{
    "nct_id": "NCT05856981",
    "official_title": "An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors",
    "inclusion_criteria": "* Male or female aged ≥18 years\n* Signed and dated informed consent form\n* Histologically and/or cytologically confirmed diagnosis of metastatic or unresectable solid tumors that are refractory to standard therapy or for which no standard therapy exists\n* Measurable disease according to RECIST (Safety Expansion only)\n* ECOG Performance status of 0 or 1\n* Adequate organ and marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients that suffer from melanoma, brain tumors, glioblastoma, sarcoma and pancreatic ductal adenocarcinoma (PDAC)\n* Pregnancy or breast-feeding\n* Prior treatment with or receipt of:\n\n  * biological agents, including monoclonal antibodies and immunotherapies, within 28 days prior to the first dose of ADU-1805\n  * chemotherapy, targeted small molecule therapy, hormonal therapy or radiation therapy within 21 days prior to the first dose of ADU-1805 and within 42 days for nitrosoureas and mitomycin C.\n  * anti-SIRPα or anti-CD47-directed therapy\n  * systemic chronic steroid therapy or immunosuppressive therapy within 14 days prior to the first dose of ADU-1805\n  * other investigational new drug or investigational device within 28 days prior to the first dose of ADU-1805\n  * vaccine containing live virus within 28 prior to the first dose of ADU-1805\n* Active untreated brain metastases\n* Active infection requiring systemic therapy\n* Impaired cardiac function or clinically significant cardiac disease\n* Current Grade >2 toxicity related to prior anti-cancer therapy\n* History of drug-induced severe immune-related adverse reaction\n* Prior severe hypersensitivity to other monoclonal antibodies or ADU-1805 excipients\n* Major surgery within defined period\n* Diagnosis or positive test of HIV, hepatitis B, hepatitis C, or active tuberculosis\n* Allogenic tissue/solid organ transplant\n* Any intercurrent illness that is life-threatening or of such clinical significance that it would interfere with the patient's safety or ability to participate in the study",
    "miscellaneous_criteria": ""
}